Optimer seeking buyout offers as CEO is shown the door

Optimer Pharmaceuticals ($OPTR) CEO Pedro Lichtinger has been shown the door--another casualty resulting from an unusual stock deal that took down the company chairman last year. And former Pfizer CEO Henry McKinnell has stepped in as interim chief while the company considers its strategic alternatives--including a possible sale. Optimer won an approval for Dificid in 2011 and has been struggling to find the right price for the antibiotic. Baird's Brian Skorney picked Pfizer and Cubist as two likely bidders for the company, which is clearly in play now. Optimer's shares shot up in early trading. Release | Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.